Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Lung Cancer

Therapeutic area intelligence for Lung Cancer with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
9
Catalysts
0
Companies
1

Companies

AstraZeneca →

Assets

Music →
Novel →
Pilot →

Recent signals(9)

ClinicalJuly 21, 2026

AstraZeneca Launches AI Study for Lung Cancer Risk Stratification

AstraZeneca is conducting an observational study to evaluate AI's role in detecting pulmonary nodules and predicting lung cancer risk in high-risk individuals.

ClinicalJuly 19, 2026

Novel CMC/CeO2 Nanocarriers Enhance Quercetin Delivery in Lung Cancer Cells

A new CMC-based nanocarrier system co-loaded with CeO2 and CQDs shows improved quercetin delivery and anticancer activity against A549 lung cancer cells.

ClinicalJuly 9, 2026

Music Therapy May Alleviate Pain and Distress in Lung Cancer Surgery Patients

A study is evaluating the effectiveness of music therapy in reducing distress and pain for lung cancer patients undergoing surgery.

ClinicalJuly 5, 2026

Trial on EBUS-TBNA with Suction for Lung Cancer Sample Collection

This trial evaluates the efficacy of EBUS-TBNA with suction in improving sample quality from suspected metastatic lung cancer patients.

ClinicalJuly 4, 2026

Study on Femtosecond Laser Imaging for Intraoperative Lung Diagnosis

A multicenter study is evaluating femtosecond laser imaging combined with AI for lung tumor diagnosis, comparing it to standard methods.

ClinicalJuly 4, 2026

Pilot Study on Immune Response After SABR in Stage I NSCLC

This pilot study aims to assess immune-mediated tumor recognition following SABR in stage I NSCLC using TCR sequencing.

ClinicalJuly 2, 2026

Pilot Study of Inhaled Cromolyn Sodium in Locally Advanced Lung Cancer

A pilot study is evaluating inhaled cromolyn sodium for safety and feasibility in patients with locally advanced lung cancer.

ClinicalJune 27, 2026

Trial on Dual Bronchodilator in COPD Patients Undergoing Lung Cancer Surgery

A randomized controlled trial is assessing the impact of dual bronchodilator therapy on COPD patients during lung cancer surgery.

ClinicalJune 20, 2026

Study Links Blood-Brain Barrier Disruption to Cognitive Impairment in Lung Cancer Patients

The study reveals a correlation between blood-brain barrier damage and cognitive impairment in untreated lung cancer patients.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Lung Cancer →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.